Human Metabolome Technologies Cuts FY2026 Earnings Forecast by 30%
Human Metabolome Technologies, Inc. (TSE:6090) has revised downward its earnings guidance for the fiscal year ending June 2026, citing weakness in life science research support services and delayed recovery in U.S. operations.
| Item | Before | After | Change |
|---|---|---|---|
| Revenue | JPY 1.60bn | JPY 1.42bn | -11.2% |
| Operating Profit | JPY 300M | JPY 210M | -30.0% |
| Ordinary Income | JPY 300M | JPY 210M | -30.0% |
| 親会社株主に帰属する当期純利益 | JPY 260M | JPY 200M | -23.1% |
| １株当たり当期純利益 | JPY 46M | JPY 36M | -22.1% |
The company attributed the revision to sluggish performance in life science research support services, delayed recovery in its U.S. business operations originally expected in the second half, and postponement of multiple large domestic projects to the following fiscal year. With a fixed-cost-heavy expense structure, the 11.2% revenue decline translates into a steeper 30% operating profit contraction, amplifying the impact on earnings.
The revision underscores heightened business uncertainty stemming from U.S. market delays and domestic project deferrals. Investors should note that ordinary income (keijo rieki)—a Japan-specific metric encompassing operating profit plus non-operating items—declined proportionally with operating profit, indicating minimal offset from financial income. Earnings per share fell 22.1% to JPY 35.59/share, reflecting the bottom-line pressure. The company’s reliance on fixed costs leaves limited flexibility to absorb revenue shortfalls, a structural risk warranting monitoring as management executes its turnaround strategy.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.